Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 21 Neoplasms 6 Neoplasm Metastasis 5 Ovarian Neoplasms 3 Endometrial Neoplasms 3 Triple Negative Breast Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Hereditary Sensory and Autonomic Neuropathies 2 Fallopian Tube Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Ovarian Epithelial 2 Breast Diseases 2 von Hippel-Lindau Disease 1 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors Refractory to Standard Therapy 1 Solid Tumor, Adult 1 Solid Tumor 1 Sarcoma 1 Recurrence 1 Rare Tumor 1 Pancreatic Neoplasms 1 Neoplasms by Site 1 Neoplasm, Residual 1 Melanoma 1 Medulloblastoma 1 Malignant Female Reproductive System Neoplasm 1 Lung Neoplasms 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Rare Tumor × palbociclib × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡